On Oct. 15, 2020, Entos Pharmaceuticals announces that its San Diego-based spinout company Aegis Life, will pursuing U.S. and international investment to support rapid development of its lead vaccine candidate. As part of a new agreement with Nature Technology Corporation (NTC), Aegis Life and Entos will use NTCﾒs proprietary Nanoplasmidﾙ plasmid DNA technology and manufacturing platform for the clinical and commercial production of theirSARS-CoV-2 vaccine, as well as other DNA vaccine candidates.